Abstract
The presence of sugammadex changes the optimal depth of muscle relaxation during general anesthesia. Anesthesiologists today often administer higher levels of rocuronium than in the past, because sugammadex can completely antagonize it. In our hospital, although we usually administer 200 mg of sugammadex as a reversal agent, the margin provided by this dosage for residual rocuronium is still unclear.
In this study, we retrospectively extracted data for rocuronium administration from 97 anesthesia records of surgical patients (ASA I/II ; anesthesia duration <2h ; minor otolaryngeal, oral, and general surgical procedures). We then calculated the total amount of rocuronium remaining in the body at the end of surgery using “Tivatrainer©”, a pharmacokinetic simulation model.
The overall levels of rocuronium and the sugammadex required to antagonize it were found to be 14.9 ± 3.9 mg (Mean ± SD) and 48.7 ± 12.9 mg, respectively.
We concluded that the dose of sugammadex normally administered in our hospital is sufficient to antagonize rocuronium remaining at the end of surgery in patients with normal metabolic function.
